Literature DB >> 31116276

What do Cochrane systematic reviews say about the management of irritable bowel syndrome?

Rafael Leite Pacheco1, Arnaldo Roizenblatt2, Aécio Flávio Teixeira de Góis3, Carolina de Oliveira Cruz Latorraca4, Carolina Frade Magalhães Girardin Pimentel Mota5, Rachel Riera6.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is a clinical disorder associated with high socioeconomic burden. Despite its importance, management of IBS remains difficult and several interventions have been hypothesized as beneficial for this condition. This study identified and summarized all Cochrane systematic reviews (SRs) about the effects of interventions for managing IBS patients. DESIGN AND
SETTING: Review of systematic reviews, carried out in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP).
METHODS: Review of Cochrane SRs addressing interventions for IBS.
RESULTS: We included six SRs assessing acupuncture, bulking agents, antispasmodics, antidepressants, herbal medicines, homeopathy, hypnotherapy and psychological therapy for IBS. The certainty of evidence ranged from unknown to moderate, mainly due to imprecision in the estimates and high risk of bias from the primary studies included. There was moderate certainty of evidence that acupuncture had no important benefit regarding improvement of symptoms and quality of life, compared with sham acupuncture. There was also very low certainty of evidence that homeopathic asafoetida, used alone or in association with nux, was better than placebo regarding self-reported overall improvement.
CONCLUSION: There was moderate certainty of evidence that acupuncture had no important benefit regarding improvement of symptoms and quality of life. Further well-designed and well-conducted randomized clinical trials are needed in order to reduce the uncertainties regarding the most commonly used interventions for patients with IBS.

Entities:  

Mesh:

Year:  2019        PMID: 31116276     DOI: 10.1590/1516-3180.2018.053740119

Source DB:  PubMed          Journal:  Sao Paulo Med J        ISSN: 1516-3180            Impact factor:   1.044


  1 in total

1.  Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders.

Authors:  Tenghao Zheng; Nicholas A Kennedy; Chris Eijsbouts; Ferdinando Bonfiglio; Carl A Anderson; Loukas Moutsianas; Joanne Holliday; Jingchunzi Shi; Suyash Shringarpure; Alexandru-Ioan Voda; Gianrico Farrugia; Andre Franke; Matthias Hübenthal; Gonçalo Abecasis; Matthew Zawistowski; Anne Heidi Skogholt; Eivind Ness-Jensen; Kristian Hveem; Tõnu Esko; Maris Teder-Laving; Alexandra Zhernakova; Michael Camilleri; Guy Boeckxstaens; Peter J Whorwell; Robin Spiller; Gil McVean; Mauro D'Amato; Luke Jostins; Miles Parkes
Journal:  Nat Genet       Date:  2021-11-05       Impact factor: 38.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.